Arbutus Biopharma Corp Restructuring, Settlement and Impairment Provisions
Arbutus Biopharma Corp (ABUS) reported Restructuring, Settlement and Impairment Provisions of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringSettlementAndImpairmentProvisions · last filed 2026-08-12
- Arbutus Biopharma Corp restructuring, settlement and impairment provisions for the quarter ending 2026-06-30 was $0.00.
- Arbutus Biopharma Corp restructuring, settlement and impairment provisions for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Arbutus Biopharma Corp restructuring, settlement and impairment provisions for the quarter ending 2025-12-31 was $0.00.
- Arbutus Biopharma Corp restructuring, settlement and impairment provisions for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Arbutus Biopharma Corp restructuring, settlement and impairment provisions for fiscal 2025 was $2.81M, a 1583.23% increase from fiscal 2024.
- Arbutus Biopharma Corp restructuring, settlement and impairment provisions for fiscal 2024 was $167.00K.
- Arbutus Biopharma Corp restructuring, settlement and impairment provisions for fiscal 2023 was $0.00.
| Period end | Restructuring, Settlement and Impairment Provisions 3 month | Restructuring, Settlement and Impairment Provisions 6 month | Restructuring, Settlement and Impairment Provisions 9 month | Restructuring, Settlement and Impairment Provisions 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | $0.00 derived: sum of 3 quarters · filed 2026-08-12 | $0.00 derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 | $0.00 derived: sum of 2 quarters · filed 2026-05-13 | $0.00 derived: sum of 3 quarters · filed 2026-05-13 | $0.00 derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $0.00 derived: sum of 2 quarters · filed 2026-03-23 | $0.00 derived: sum of 3 quarters · filed 2026-08-12 | $2.81M 10-K · filed 2026-03-23 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-12 | $2.81M 10-Q · filed 2025-11-13 | $2.81M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.81M 10-Q · filed 2026-08-12 | $2.81M derived: sum of 3 quarters · filed 2026-08-12 | $2.98M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $2.81M 10-Q · filed 2026-05-13 | $2.81M derived: sum of 2 quarters · filed 2026-05-13 | $2.98M derived: sum of 3 quarters · filed 2026-05-13 | $2.98M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $167.00K derived: sum of 2 quarters · filed 2026-03-23 | $167.00K derived: sum of 3 quarters · filed 2026-03-23 | $167.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $167.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $167.00K derived: sum of 2 quarters · filed 2025-11-13 | $167.00K 10-Q · filed 2025-11-13 | $167.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | $0.00 derived: sum of 3 quarters · filed 2025-08-06 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 | $0.00 derived: sum of 2 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $0.00 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |